ReviewJournal of experimental orthopaedics2026
Patient-reported outcomes after anterior cruciate ligament reconstruction with the JewelACL synthetic ligament: Multicenter study of at least 9 years follow-up.
Review in Journal of experimental orthopaedics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Synthetic grafts for anterior cruciate ligament (ACL) reconstruction aim to address limitations of biological grafts, such as donor-site morbidity and delayed recovery. JewelACL is a synthetic scaffold developed to enhance biological integration and mechanical durability. This multicenter study evaluated long-term patient-reported outcomes, adverse events, re-rupture rates and return-to-sport outcomes following ACL reconstruction using JewelACL, with a minimum follow-up of 9 years. Methods: A retrospective cohort of 58 patients who underwent ACL reconstruction between 2010 and 2014, using either JewelACL alone ( Results: At a mean follow-up of 10.8 ± 0.9 years, the re-rupture rate was (5.2%) 3 cases out of 58. Median Lysholm and IKDC scores were 100 (interquartile range [IQR] 91-100) and 95 (IQR 89-99), respectively, indicating excellent long-term knee function. The mean Tegner score at follow-up was 5.2 ± 1.7, representing a modest decline from the pre-injury level of 6.5, consistent with age-related reductions in activity. No patient-reported infections or hospital admissions related to the operated knee were reported. IKDC scores were significantly higher in the JewelACL-only group than in the hybrid group ( Conclusions: ACL reconstruction using JewelACL was associated with excellent long-term PROMs, low re-rupture rates and high return-to-sport rates. Although these findings are encouraging, interpretation is limited by the retrospective design, substantial loss to follow-up and the absence of imaging or objective clinical assessments. There was no statistically significant difference in return-to-sport rates between the JewelACL group (85%) and the hybrid group (86%) ( Level of Evidence: Level IV.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.